company background image
002880 logo

Shenzhen Weiguang Biological Products SZSE:002880 Stock Report

Last Price

CN¥28.15

Market Cap

CN¥6.4b

7D

-4.8%

1Y

-19.6%

Updated

24 Dec, 2024

Data

Company Financials +

Shenzhen Weiguang Biological Products Co., Ltd.

SZSE:002880 Stock Report

Market Cap: CN¥6.4b

002880 Stock Overview

Shenzhen Weiguang Biological Products Co., Ltd. More details

002880 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Shenzhen Weiguang Biological Products Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shenzhen Weiguang Biological Products
Historical stock prices
Current Share PriceCN¥28.15
52 Week HighCN¥35.86
52 Week LowCN¥22.05
Beta0.065
1 Month Change1.99%
3 Month Change16.13%
1 Year Change-19.57%
3 Year Change-11.20%
5 Year Change13.14%
Change since IPO63.48%

Recent News & Updates

Recent updates

Shareholder Returns

002880CN BiotechsCN Market
7D-4.8%-3.0%-2.1%
1Y-19.6%-19.0%9.8%

Return vs Industry: 002880 matched the CN Biotechs industry which returned -19% over the past year.

Return vs Market: 002880 underperformed the CN Market which returned 9.8% over the past year.

Price Volatility

Is 002880's price volatile compared to industry and market?
002880 volatility
002880 Average Weekly Movement5.5%
Biotechs Industry Average Movement8.9%
Market Average Movement8.8%
10% most volatile stocks in CN Market13.0%
10% least volatile stocks in CN Market5.8%

Stable Share Price: 002880 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 002880's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985846Caiping Guowww.szwg.com

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous human immunoglobulin (pH4), rabies immunoglobulin, human fibrinogen, coagulation factor, trace proteins, as well as a total of 9 varieties and 21 specifications.

Shenzhen Weiguang Biological Products Co., Ltd. Fundamentals Summary

How do Shenzhen Weiguang Biological Products's earnings and revenue compare to its market cap?
002880 fundamental statistics
Market capCN¥6.38b
Earnings (TTM)CN¥250.11m
Revenue (TTM)CN¥1.17b

25.5x

P/E Ratio

5.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
002880 income statement (TTM)
RevenueCN¥1.17b
Cost of RevenueCN¥692.85m
Gross ProfitCN¥474.32m
Other ExpensesCN¥224.21m
EarningsCN¥250.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.10
Gross Margin40.64%
Net Profit Margin21.43%
Debt/Equity Ratio29.7%

How did 002880 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:59
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Weiguang Biological Products Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.